enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Calcilytic - Wikipedia

    en.wikipedia.org/wiki/Calcilytic

    Consequently, these drugs have been researched for the treatment of osteoporosis, [2] [3] [4] though with only limited success. [5] More recent research has suggested a number of additional applications for these drugs, such as hyperresponsiveness and inflammation in allergic asthma. [6] [7] [8] [9]

  3. Bisphosphonate - Wikipedia

    en.wikipedia.org/wiki/Bisphosphonate

    Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone. In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.

  4. Strontium ranelate - Wikipedia

    en.wikipedia.org/wiki/Strontium_ranelate

    Strontium ranelate, a strontium(II) salt of ranelic acid, is a medication for osteoporosis marketed as Protelos or Protos by Servier. Studies indicate it can also slow the course of osteoarthritis of the knee. [1] The drug is unusual in that it both increases deposition of new bone by osteoblasts and reduces the resorption of bone by ...

  5. Category:Osteoporosis drugs - Wikipedia

    en.wikipedia.org/wiki/Category:Osteoporosis_drugs

    Print/export Download as PDF; Printable version; In other projects ... Pages in category "Osteoporosis drugs" The following 5 pages are in this category, out of 5 ...

  6. Osteoporosis - Wikipedia

    en.wikipedia.org/wiki/Osteoporosis

    Romosozumab (sold under the brand name Evenity) is a monoclonal antibody against sclerostin. Romosozumab is usually reserved for patients with very high fracture risk and is the only available drug therapy for osteoporosis that leads to simultaneous inhibition of bone resorption together with an anabolic effect. [182] [183]

  7. Merck Announces Osteoporosis Drug Success - AOL

    www.aol.com/news/2012-10-15-merck-announces-new...

    Pharmaceutical giant Merck (NYS: MRK) reported promising results from a phase II drug trial for its new osteoporosis drug, odanacatib. Merck plans to submit applications for the drug to U.S ...

  8. Merck Announces Osteoporosis Drug Success - AOL

    www.aol.com/2012/10/15/merck-announces-new-drug...

    For premium support please call: 800-290-4726 more ways to reach us

  9. Denosumab - Wikipedia

    en.wikipedia.org/wiki/Denosumab

    Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. [11] [12] The most common side effects are joint and muscle pain in the arms or legs. [13]